Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virus.

BACKGROUND The objectives of this study were to determine (i) the prevalence of oral Epstein-Barr virus (EBV) in HIV-infected subjects compared to non-HIV controls and (ii) the effects of long-term use of antiretroviral therapy (ART) on the prevalence of oral EBV. METHODS A cross-sectional study was performed in HIV-infected subjects with and without ART, and non-HIV individuals. DNA in saliva samples was extracted and used as a template to detect EBV BamH1W and EBNA1 by quantitative polymerase chain reaction. Student t-test and ANOVA test were performed to determine the prevalence rates among groups. RESULTS Forty-nine HIV-infected subjects: 37 on ART (age range 23-54 year, mean 37 year), 12 not on ART (age range 20-40 year, mean 31 year), and 20 non-HIV controls (age range 19-53 year, mean 31 year) were enrolled. The numbers of EBV BamH1W in saliva were found to be significantly higher in HIV-infected subjects than non-HIV controls (80% vs. 20%, mean = 12118 vs. 134 copies/10(5) cells, P < 0.001). HIV-infected subjects who were on ART had significantly lower numbers of EBV BamH1W than those who were not (mean = 4102 vs. 138613 copies/10(5) cells, P = 0.011). The numbers were significantly lower in those who received long-term ART compared with short-term (mean = 1401 vs. 11124 copies/10(5) cells, P = 0.034). No significant difference was observed between the groups when using EBNA1 primers. CONCLUSIONS Prevalence of oral EBV was significantly higher in HIV-infected subjects than non-HIV-controls. The numbers of the virus were significantly decreased by ART. Long-term use of ART did not increase oral EBV.

[1]  S. Silva,et al.  HIV, EBV and KSHV: Viral cooperation in the pathogenesis of human malignancies , 2011 .

[2]  F. Biniaz,et al.  Evaluation of Epstein-Barr virus load in saliva before and after renal transplantation. , 2011, Transplantation proceedings.

[3]  K. Bhatia,et al.  Cancer biomarkers in HIV patients , 2010, Current opinion in HIV and AIDS.

[4]  Hsin-Yun Sun,et al.  Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan. , 2010, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[5]  S. Chakrabarti,et al.  Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario , 2010, Virology Journal.

[6]  S. Talungchit,et al.  Effects of long-term use of HAART on oral health status of HIV-infected subjects. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[7]  K. Stoltze,et al.  Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[8]  A. Porwit,et al.  Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association , 2010, BMC Cancer.

[9]  D. Klein,et al.  HIV infection and the risk of cancers with and without a known infectious cause , 2009, AIDS.

[10]  L. Gergely,et al.  Epstein-Barr virus prevalence in oral squamous cell cancer and in potentially malignant oral disorders in an eastern Hungarian population. , 2009, European journal of oral sciences.

[11]  N. Rothman,et al.  A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. , 2009, Blood.

[12]  M. Gillison.  Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection , 2009, Current opinion in oncology.

[13]  B. Gazzard,et al.  CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK , 2009, Haematologica.

[14]  E. Engels.  Non-0002030-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities , 2009, AIDS.

[15]  M. Núñez,et al.  Longer Duration of HBV-Active Antiretroviral Therapy is Linked to Favorable Virological Outcome in HIV-HBV Co-infected Patients , 2009, HIV clinical trials.

[16]  R. Mitsuyasu.  Non--AIDS-defining malignancies in HIV. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[17]  A. Deyrup.  Progress in pathology Epstein-Barr virus – associated epithelial and mesenchymal neoplasms , 2008 .

[18]  K. Shroyer,et al.  Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. , 2008, Human pathology.

[19]  W. Jia,et al.  [Correlation of Epstein-Barr virus A73 gene polymorphisms to susceptibility to nasopharyngeal carcinoma]. , 2007, Ai zheng = Aizheng = Chinese journal of cancer.

[20]  D. Spandidos,et al.  Concurrent CMV and EBV DNAemia is significantly correlated with a delay in the response to HAART in treatment-naive HIV type 1-positive patients. , 2007, AIDS research and human retroviruses.

[21]  Craig S. Miller,et al.  High Prevalence of Multiple Human Herpesviruses in Saliva from Human Immunodeficiency Virus-Infected Persons in the Era of Highly Active Antiretroviral Therapy , 2006, Journal of Clinical Microbiology.

[22]  F. Miedema,et al.  Long-Term Highly Active Antiretroviral Therapy in Chronic HIV-1 Infection: Evidence for Reconstitution of Antiviral Immunity , 2006, Antiviral therapy.

[23]  C. Hung,et al.  Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. , 2005, International journal of STD & AIDS.

[24]  F. Miedema,et al.  Reconstitution of EBV Latent but Not Lytic Antigen-Specific CD4+ and CD8+ T Cells after HIV Treatment with Highly Active Antiretroviral Therapy 1 , 2005, The Journal of Immunology.

[25]  Craig S. Miller,et al.  Effect of Prophylactic Valacyclovir on the Presence of Human Herpesvirus DNA in Saliva of Healthy Individuals after Dental Treatment , 2005, Journal of Clinical Microbiology.

[26]  M. Riera,et al.  Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. , 2005, European journal of internal medicine.

[27]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[28]  M. Gulley,et al.  Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. , 2004, The Journal of molecular diagnostics : JMD.

[29]  A. Antinori,et al.  Positive predictive value of Epstein-Barr virus DNA detection in HIV-related primary central nervous system lymphoma. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  S. Preston‐Martin,et al.  Cancer Risk Among Participants in the Women’s Interagency HIV Study , 2004, Journal of acquired immune deficiency syndromes.

[31]  W. Keitel,et al.  Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Jaap M Middeldorp,et al.  High Epstein–Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology , 2002, AIDS.

[33]  K. Brengel-Pesce,et al.  Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections , 2002, Journal of medical virology.

[34]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[35]  G. T. Jones,et al.  Classification and diagnostic criteria for oral lesions in HIV infection , 1994 .